On Jun. 30, 2021, Atea Pharmaceuticals announced positive interim results from the global Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate COVID-19. Roche and Atea are jointly developing AT-527, an oral direct-acting antiviral (DAA) agent derived from Ateaﾒs purine nucleotide prodrug platform.